Angiotensin III (human, mouse): Structure, Mechanism, and Research Benchmarks

Executive Summary: Angiotensin III (human, mouse) is a biologically active hexapeptide generated by enzymatic cleavage of angiotensin II, possessing the sequence Arg-Val-Tyr-Ile-His-Pro-Phe and a molecular weight of 931.09 Da (APExBIO product A1043). It modulates the renin-angiotensin-aldosterone system (RAAS) by mediating ~40% of angiotensin II's pressor activity and fully inducing aldosterone secretion (Oliveira et al., 2025). Angiotensin III interacts with AT1 and AT2 receptors, showing a preference for AT2 in some contexts. In vivo, exogenous administration suppresses renin and stimulates aldosterone, paralleling angiotensin II. The peptide is highly soluble in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL), and is optimally stable when stored desiccated at -20°C (APExBIO).

Biological Rationale

Angiotensin III (human, mouse) is a validated component of the renin-angiotensin-aldosterone system (RAAS), a peptide hormone cascade crucial for cardiovascular homeostasis, fluid balance, and blood pressure regulation (Oliveira et al., 2025). It is generated in vivo via N-terminal cleavage of angiotensin II by aminopeptidases, notably in erythrocytes and various tissues. Angiotensin III plays a significant physiological role by maintaining basal blood pressure, mediating vasoconstriction, and regulating aldosterone release from the adrenal cortex. While angiotensin II is the primary RAAS effector, angiotensin III contributes substantially to the pressor response and is crucial for fine-tuning neuroendocrine and renal responses. Its presence and activity have been documented in human and rodent systems, making it a relevant model for translational research (see also).

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III exerts its effects primarily via binding to angiotensin II receptor subtypes AT1 and AT2, both G protein-coupled receptors (GPCRs) expressed in cardiovascular, renal, and neural tissues. The hexapeptide sequence (Arg-Val-Tyr-Ile-His-Pro-Phe) allows for high-affinity receptor interaction. Upon binding AT1, Angiotensin III triggers vasoconstriction and aldosterone secretion, though with reduced pressor potency (~40%) compared to angiotensin II (Oliveira et al., 2025). Its action at the AT2 receptor is associated with anti-proliferative and vasodilatory effects, and studies suggest a relative specificity for AT2 versus AT1 when compared to angiotensin II. In the central nervous system, Angiotensin III induces dipsogenic (thirst-inducing) and pressor responses, underscoring its neuroendocrine relevance (see mechanistic review).

Evidence & Benchmarks

• Angiotensin III (2–8) is produced by aminopeptidase-mediated N-terminal cleavage of angiotensin II (1–8) in mammalian tissues (Oliveira et al., 2025).
• It mediates approximately 40% of the pressor activity of angiotensin II in vivo, yet retains full capacity to stimulate aldosterone secretion (Oliveira et al., Table 1).
• Exogenous Angiotensin III suppresses renin release and increases aldosterone levels in rodent models, paralleling angiotensin II (internal summary).
• In rodent brain studies, Angiotensin III administration elicits rapid pressor and dipsogenic responses, confirming its neuroendocrine activity (mechanistic review).
• Angiotensin III interacts with both AT1 and AT2 receptors, with evidence for relative specificity toward AT2; this influences vasodilation and anti-proliferative signaling (Oliveira et al., Figure 1).
• Peptides derived from Angiotensin II, including Angiotensin III, modulate SARS-CoV-2 spike protein binding to the AXL receptor, suggesting new roles in viral pathogenesis research (Oliveira et al., Results).
• The molecular formula of Angiotensin III is C46H66N12O9; it is a solid, highly soluble in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL) at ambient temperature (APExBIO datasheet).

This article incorporates and updates information presented in 'Angiotensin III (human, mouse): A Key RAAS Peptide for Cardiovascular Research' by providing new evidence on viral pathogenesis roles and improved solubility parameters. For advanced molecular perspectives, see 'Angiotensin III: Molecular Insights and Translational Research'; this article integrates those molecular insights with quantitative benchmarks for laboratory use.

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) from APExBIO (A1043) is used extensively in cardiovascular, neuroendocrine, and emerging infectious disease research as a tool for dissecting RAAS function, receptor pharmacology, and peptide signaling. It is a validated standard in hypertension model systems, allowing precise quantification of AT1 and AT2 mediated effects. Additionally, recent findings implicate RAAS peptides, including Angiotensin III, in modulating SARS-CoV-2 spike protein binding—expanding its relevance to viral pathogenesis models (Oliveira et al., 2025).

Common Pitfalls or Misconceptions

• Angiotensin III does not fully recapitulate all biological effects of angiotensin II; its pressor activity is lower (~40%) and context-dependent (Oliveira et al.).
• Long-term storage in solution is not recommended; peptide integrity is best maintained desiccated at -20°C (APExBIO).
• Functional readouts can be confounded by peptidase activity in biological matrices; in vitro stability may differ from in vivo application (mechanistic review).
• Not all receptor effects are equivalent; specificity for AT2 versus AT1 may vary by tissue and experimental design (molecular insights).

Workflow Integration & Parameters

For experimental use, Angiotensin III (human, mouse) is provided as a solid and should be reconstituted according to required solvent compatibility. Typical concentrations for in vitro studies range from 0.1 μM to 10 μM; for in vivo infusion, dosing must be titrated based on animal weight and target tissue (APExBIO). The peptide is highly soluble in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), and DMSO (≥93.1 mg/mL). For optimal stability, store aliquots desiccated at -20°C and avoid repeated freeze-thaw cycles. Do not store long-term in solution. Analytical verification (e.g., HPLC, MS) is recommended post-reconstitution for quantitative applications. Use validated controls, including angiotensin II, to benchmark receptor-specific responses. For detailed mechanistic strategies, see 'Angiotensin III: Molecular Insights and Current Research Models', which this article extends by specifying workflow parameters and storage criteria.

Conclusion & Outlook

Angiotensin III (human, mouse) is a versatile RAAS peptide, critical for cardiovascular, neuroendocrine, and infectious disease research. Its distinct receptor profile and solubility make it a valuable standard for experimental modeling. Ongoing research, including modulation of viral protein interactions, suggests broader implications beyond traditional RAAS paradigms. For product specifications, refer to the APExBIO A1043 product page.